The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 07, 2021
Filed:
Sep. 13, 2019
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventor:
David R. Elmaleh, Newton, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/5415 (2006.01); A61K 45/06 (2006.01); A61K 31/192 (2006.01); A61K 31/352 (2006.01); A61K 31/428 (2006.01); A61K 31/438 (2006.01); A61K 31/706 (2006.01); A61K 31/047 (2006.01); A61K 31/225 (2006.01); A61K 31/435 (2006.01); A61K 51/04 (2006.01); A61K 31/13 (2006.01); A61K 31/194 (2006.01); A61K 31/075 (2006.01); A61K 31/55 (2006.01); A61K 31/713 (2006.01); A61K 38/18 (2006.01); A61K 39/00 (2006.01); C07K 16/18 (2006.01); A61K 31/353 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/5415 (2013.01); A61K 31/047 (2013.01); A61K 31/075 (2013.01); A61K 31/13 (2013.01); A61K 31/192 (2013.01); A61K 31/194 (2013.01); A61K 31/225 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/428 (2013.01); A61K 31/435 (2013.01); A61K 31/438 (2013.01); A61K 31/55 (2013.01); A61K 31/706 (2013.01); A61K 31/713 (2013.01); A61K 38/185 (2013.01); A61K 39/0005 (2013.01); A61K 45/06 (2013.01); A61K 51/0453 (2013.01); C07K 16/18 (2013.01); A61K 48/00 (2013.01);
Abstract
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.